A multicenter study to evaluate the efficacy and safety of a 5 week therapy with the combination of valsartan 160 mg plus amlodipine 10 mg in hypertensive patients not adequately responding to a 5 week therapy with ramipril 5 mg and felodipine 5 mg.
Phase of Trial: Phase III
Latest Information Update: 24 May 2017
At a glance
- Drugs Amlodipine; Valsartan
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Novartis
- 11 Oct 2006 New trial record.